Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 12, 2012 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners to Announce Top-Line Data From CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction Earlier Than Expected

CORAL GABLES, Fla., July 12, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that it expects to report top-line results from its CPP-109 (vigabatrin)...
June 28, 2012 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Scientific Paper Describing the Ocular Safety of Short-Term Vigabatrin Treatment for Cocaine Addiction in Online Edition of American Journal of Ophthalmology

CORAL GABLES, Fla., June 28, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that an ePublication on CPP-109 (vigabatrin) describing ocular safety results...
June 21, 2012 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Receives Guidance From NASDAQ Regarding Minimum Bid Price Requirement

CORAL GABLES, Fla., June 21, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that it received a Nasdaq Staff Deficiency Letter dated June 18, 2012...
June 07, 2012 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners to Present CPP-115 Progress at the 2012 College on Problems of Drug Dependence Symposium

CORAL GABLES, Fla., June 7, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that Steven R. Miller, Ph.D., Catalyst's Chief Operating Officer and Chief...
May 30, 2012 13:30 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Closes Underwritten Offering

CORAL GABLES, Fla., May 30, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced the successful closing of the previously announced underwritten offering of...
May 24, 2012 08:45 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Prices Underwritten Offering

CORAL GABLES, Fla., May 24, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced the pricing of an underwritten offering of 6,000,000 units, with each unit...
May 22, 2012 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Reports Positive Results From Phase I(a) Clinical Study of CPP-115

CORAL GABLES, Fla., May 22, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced positive results from a Phase I(a) study to evaluate the safety, tolerability...
May 21, 2012 11:00 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Announces Completion of Enrollment in CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction

CORAL GABLES, Fla., May 21, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced that patient enrollment in its CPP-109 vigabatrin Phase II(b) clinical trial...
May 16, 2012 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Announces First Quarter 2012 Financial Results

CORAL GABLES, Fla., May 16, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the three month period ended March 31, 2012. The...
April 02, 2012 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2011 Financial Results

CORAL GABLES, Fla., April 2, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company that focuses on the development and commercialization of...